The short version of Synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-06. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Indonesia, in recent years, has progressively liberalized its visa regime, no longer requiring visas or on-arrival visas from most nationals, while Singapore has signed visa waiver agreements with many countries in recent years and has introduced electronic visa facilities for Indians, Eastern Europeans, and mainland Chinese. This trend towards visa liberalisation in Asia is part of the regional trend toward social and economic globalisation that has been linked to heightened economic growth. Certain countries, predominantly, though not exclusively, in Western Europe and the Americas, issue working holiday visas for younger visitors to supplement their travel funds by working in minor jobs. These are especially common among members of the European Union and elsewhere in Europe. Saudi Arabia issues a special category visa for people on religious pilgrimage. Similar policies are in force in other countries with significant religious sites. Certain jurisdictions impose special visa requirements on journalists. Countries that require such visas include Cuba, China, North Korea, Saudi Arabia, America, and Zimbabwe. As a consequence of awkward border situations created by the fall of the Soviet Union, certain former members of the USSR and their neighbours maintain special visa-exemption policies for travellers transiting across international boundaries within a single country. For instance, Russia permits vehicles to transit through the Saatse Boot between the Estonian villages of Lutepää and Sesniki without a visa or border checkpoint, provided they do not stop.
paracellular transport The transfer of substances across an epithelium by passing through the extracellular space between cells, in contrast to transcellular transport, where substances travel through cells by crossing the intracellular cytoplasm.
He prevailed over Etcheverry in four sets to reach his third consecutive semi-final at this tournament. He fell in his semi-final match to world No. 4 and last year finalist, Casper Ruud, in straight sets. Zverev began his grass season by withdrawing from the BOSS Open in Stuttgart due to a thigh injury that he picked up during his semifinal match at Roland Garros. Zverev then defeated Dominic Thiem, Denis Shapovalov, and Nicolas Jarry in Halle to reach the semifinals where he lost to eventual champion Alexander Bublik. At Wimbledon, Zverev lost in third round to Matteo Berrettini. In Båstad, Zverev lost in the quarterfinals to Andrey Rublev. Zverev won the Hamburg European Open, defeating Laslo Djere in the final. His triumph marked his 20th career ATP Title. During his 2023 US Open match against Jannik Sinner, Zverev halted play and complained to officials in response to a fan shouting the opening stanza to "Deutschlandlied", a song which has served as the national anthem of Germany; the use of the first and second stanza are presently commonly discouraged because of history. Alexander Zverev interpreted this as carrying Nazi sentiment and told officials that the fan had shouted, "the most famous Hitler phrase". Zverev lost the quarterfinals match against Carlos Alcaraz after winning a 4-hour 40 minutes five-set match against Jannik Sinner. This match, in combination with the Roland Garros 2023 semi-final, cemented Zverev's return to top form. His performance in the Asian swing was marked by his 21st title in Chengdu, defeating Roman Safiullin in three sets.
Sources: en.wikipedia.org
=== Other activities === High has been on NIH study sections for hematology and for therapeutic approaches to genetic disease. She was on the National Heart, Lung and Blood Advisory Council, on the NIH Clinical Center Advisory Council, and on the Board of Scientific Counsellors for the National Eye Institute. She did a four year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapy (2001–2005) and was the President of the American Society of Gene and Cell Therapy (2004–2005).
=== Pure element applications === Molybdenum powder is used as a fertilizer for some plants, such as cauliflower. Elemental molybdenum is used in NO, NO2, NOx analyzers in power plants for pollution controls. At 350 °C (662 °F), the element acts as a catalyst for NO2/NOx to form NO molecules for detection by infrared light. Molybdenum anodes replace tungsten in certain low voltage X-ray sources for specialized uses such as mammography. The radioactive isotope molybdenum-99 is used to generate technetium-99m, a short-lived daughter radionuclide (t½ ≃ 6.0 h) needed for medical imaging. The radioisotope is handled and stored as the molybdate (MoO2−4).
Golden Wings (From the beginning to 18:30) "Spiral Labyrinth" (Gaiden 2, episodes 1–14) "Silver-White Valley" (Gaiden 1, episodes 1–4) "The Mutineer" (Gaiden 2, ep. 15–18) "The Duelist" (Gaiden 2, ep. 19–22) Golden Wings (From 18:30 to the end) "The Retriever" (Gaiden 2, ep. 23–26) "Dream of the Morning, Song of Night" (Gaiden 1, ep. 5–8) "A Hundred Billion Stars, a Hundred Billion Lights" (Gaiden 1, ep. 13–24) "The Third Tiamat Battle" (Gaiden 2, ep. 27–28) My Conquest is the Sea of Stars Overture to a New War (From the beginning to 35:40) "Disgrace" (Gaiden 1, ep. 9–12) Overture to a New War (from 35:40 to the end) Main OVA series (The first two episodes have an expanded retelling in Overture to a New War)
==== Horticulture ==== Some horticulturists and users of hydroponics advocate the use of weak hydrogen peroxide solution in watering solutions. Its spontaneous decomposition releases oxygen that enhances a plant's root development and helps to treat root rot (cellular root death due to lack of oxygen) and a variety of other pests. For general watering concentrations, around 0.1% is in use. This can be increased up to one percent for antifungal actions. Tests show that plant foliage can safely tolerate concentrations up to 3%.
Sources: en.wikipedia.org
5 August – The 18th century Crooked House, once known as "Britain's wonkiest pub", is gutted by a fire. The pub is demolished two days later. Police subsequently confirm they are treating the fire as arson. 6 August Secretary of State for Justice Alex Chalk confirms that the rule deducting living costs from compensation paid to people who have been wrongfully convicted will be scrapped. Greetings card retailer Clintons are to close around 20% of their outlets to cut back on expenditure. 7 August – The first group of asylum seekers to be housed on the Bibby Stockholm while they wait for the cases to be processed arrive on the barge following delays over safety concerns. 8 August The Police Service of Northern Ireland issues an apology after a data breach led to the details of its officers being published online. The Electoral Commission warns people to look out for unauthorised use of their data after revealing it was the victim of a "complex cyber-attack" in August 2021, which was not discovered until October 2022. The Joint Committee on Vaccination and Immunisation recommends the Autumn 2023 programme of COVID-19 booster vaccines should be routinely offered to all over-65s, as well as those under 65 in clinical risk groups, care home residents and frontline health workers. This marks a change from 2022 when all adults over 50 were offered the booster. The flu vaccine will also be offered to over 65s after the age was dropped to 50 during the pandemic.
Recent advancements in bioorthogonal chemistry have revealed applications in protein analysis. The extension of using organic molecules to observe their reaction with proteins reveals extensive methods to tag them. Unnatural amino acids and various functional groups represent new growing technologies in proteomics. Specific biomolecules that are capable of being metabolized in cells or tissues are inserted into proteins or glycans. The molecule will have an affinity tag, modifying the protein allowing it to be detected. Azidohomoalanine (AHA) utilizes this affinity tag via incorporation with Met-t-RNA synthetase to incorporate into proteins. This has allowed AHA to assist in determine the identity of newly synthesized proteins created in response to perturbations and to identify proteins secreted by cells. Recent studies using ketones and aldehydes condensations show that they are best suited for in vitro or cell surface labeling. However, using ketones and aldehydes as bioorthogonal reporters revealed slow kinetics indicating that while effective for labeling, the concentration must be high. Certain proteins can be detected via their reactivity to azide groups. Non-proteinogenic amino acids can bear azide groups which react with phosphines in Staudinger ligations. This reaction has already been used to label other biomolecules in living cells and animals. The bioorthogonal field is expanding and is driving further applications within proteomics. It is worthwhile noting the limitations and benefits.
In molecular biology, the condensation domain is a protein domain found in many multi-domain enzymes which synthesise peptide antibiotics. This domain catalyses a condensation reaction to form peptide bonds in non-ribosomal peptide biosynthesis. It is usually found to the carboxy side of a phosphopantetheine binding domain (pp-binding). It has been shown that mutations in the HHXXXDG sequence motif in this domain abolish activity suggesting this is part of the active site.
with a similar structure in 2D. Thus the governing equation is an integro-differential equation similar to Coulomb's and Biot–Savart's law, not convenient for numerical computation. An equivalent weak or variational form of the equation, proved to produce the same velocity solution as the Navier–Stokes equation, is given by,
=== Australia === The conservative Liberal–National Coalition issued a statement welcoming the news, with leader Sussan Ley remarking that "We should live in a world where dictators and despots face justice for their crimes." The Greens defense spokesman David Shoebridge condemned the operation as a breach of international law that "continues the world on a dangerous path of lawless aggression." Labor Against War, a political group within the ruling Labor Party, called on the government to condemn the strikes and to "immediately distance itself from the Trump administration, whose conduct is marked by [...] lawlessness at home and violent, reckless coercion abroad".
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.